T Filleron
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh M, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2015; 27:281-6.
Nov 23, 2015Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Nov 23, 2015Ann Oncol 2015; 27:281-6
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh Martin, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015
Oct 13, 2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Oct 13, 2015Ann Oncol 2015
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.
Feb 27, 2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Feb 27, 2015Ann Oncol 2015; 26:873-9
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S